The Qualification Test That Redraws the AI Device Line

The threshold question most AI roadmaps skip

Most life sciences AI governance work starts one step too late. Teams build risk frameworks, conformity plans, and post-market surveillance protocols for tools they have already labeled “clinical decision support” or “informational,” on the assumption that self-declared intended purpose settles the question of whether MDR or IVDR applies at all. A recent EU Court judgment says that assumption no longer holds. The ruling clarifies that the medical device qualification test weighs objective function alongside declared intended purpose, meaning a tool’s actual technical behavior, not just its marketing language, can pull it into device scope regardless of how the developer characterized it at launch, per Sidley’s GoodLifeSci analysis.

This is a scope problem, not a classification problem. Classification questions (Class I versus IIa versus IIb) assume you have already established that a device exists. This judgment reopens the prior question for a category of generative and predictive AI tools that vendors positioned as outside MDR/IVDR precisely to avoid conformity assessment. Medical Device Coordination Group guidance and existing classification rules remain the reference point, but the qualification test itself just got more demanding, per the same Sidley analysis.

Why the conformity assessment stakes just rose

If a tool moves from “not a device” to “device,” it does not enter a lighter track. It walks straight into the convergence that ISO 13485 and ISO 42001 were built to handle jointly. Under Article 43(3) of the EU AI Act, the same Notified Body assessing MDR or IVDR conformity can also assess the AI Act’s high-risk requirements in a single review, which is efficient if you planned for it and costly if you didn’t, as DataArt’s analysis of the integrated system lays out. Procurement guidance confirms the same logic operationally: once an AI tool qualifies as a device, MDR or IVDR conformity and CE marking apply on top of AI Act obligations, not instead of them, per Global Law Experts’ Austria procurement guide. The dual-compliance clock is already running, with an August 2026 deadline for integrated MDR and EU AI Act conformity assessment cited in current market guidance, per AlphaIndigo’s regulatory tracker.

The decision in front of compliance leaders

Every AI-enabled clinical tool your organization currently treats as exempt deserves a fresh qualification review against this objective-function test, not a fresh classification memo. Waiting for a classification dispute to surface the scope question is the expensive way to find out. The cheaper path is running the qualification test now, before a Notified Body or regulator runs it for you.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that objective function now matters for device qualification, not just declared purpose—is coherent and well-supported by the cited Sidley analysis, though the piece slightly oversta
Source & Claim Verification	Qwen · local	cleared. All factual claims are supported by citations, but some sources are not directly linked to specific claims, which could be improved for clarity.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the EU Court judgment’s impact on MDR/IVDR qualification and aligns with ISO 42001 and EU AI Act integration, but lacks explicit FDA/MDR/IVDR technical specificity for
Technical Accuracy	Llama	cleared. The article accurately reflects the recent EU Court judgment on the medical device qualification test, correctly emphasizing the consideration of both objective function and intended purpose, and its
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively uses counterarguments by highlighting common misconceptions and directly refuting them with legal and regulatory developments, while carefully attributing vendor-sourced infor
Novelty & Non-Duplication	Grok	held. The piece mainly repackages one Sidley alert on a CJEU qualification judgment plus widely circulated MDR/AI Act convergence points, so it lacks a clearly non-duplicative hook versus the wire.
Validation	DeepSeek	cleared. The central claim that an EU Court judgment has made the medical device qualification test more demanding by weighing objective function is validated by the cited legal analysis, though the briefing’s

Sources cited: 15. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.